FN18-CRM9 immunotoxin promotes tolerance in primate renal allografts

Transplantation
S J KnechtleD M Neville

Abstract

Transplant tolerance, rather than immunity, may be favored in the setting of a lower mature lymphoid mass in the recipient induced by anti-T cell agents. A novel immunosuppressive agent, FN18-CRM9, known to specifically kill T cells with great potency, was evaluated in a transplant model. In order to ablate recipient T cells, the immunotoxin FN18-CRM9 was administered to rhesus monkey recipients of MHC-mismatched renal allografts. Donor lymphocytes were injected intrathymically into some animals. All monkeys with T-cell depletion by immunotoxin had prolonged allograft survival, and tolerance confirmed by skin grafting has been confirmed in five of six long-surviving recipients. In this clinically relevant model, profound but transient T-cell depletion by a single agent substantially promotes tolerance.

References

Apr 11, 1992·Proceedings of the National Academy of Sciences of the United States of America·D M NevilleK Srinivasachar
Jan 1, 1992·Immunogenetics·B Levins, C A Colaco
Jan 1, 1992·Immunogenetics·G LevinsonN L Letvin
Sep 1, 1988·European Journal of Immunology·D I WatkinsN L Letvin
Mar 27, 1994·Transplantation·J A PowelsonA B Cosimi
Mar 1, 1996·Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy·D M NevilleM Jonker

❮ Previous
Next ❯

Citations

Oct 3, 2003·Journal of Pediatric Surgery·Marion M Aw
Jul 5, 2003·The Journal of Surgical Research·Rebecca A SchroederPaul C Kuo
Dec 26, 2001·Transplantation Proceedings·A D Salamam, M H Sayegh
Dec 26, 2001·Transplantation Proceedings·S J Knechtle
May 30, 2002·Transplantation Proceedings·R Loertscher
May 14, 2003·Transplantation Proceedings·R Y Calne
Sep 2, 1998·Transplantation Proceedings·S J KnechtleM M Hamawy
May 20, 1999·Transplantation Proceedings·S J KnechtleD M Harlan
Jun 18, 1999·Transplantation Proceedings·A B Cosimi
Aug 24, 1999·Transplantation Proceedings·S KoH J Schlitt
Sep 28, 2000·Current Opinion in Immunology·S J Knechtle
Aug 17, 2002·Current Opinion in Immunology·Scott H Adler, Laurence A Turka
Oct 31, 1998·Current Opinion in Immunology·M M Hamawy, S J Knechtle
Oct 6, 1999·Current Opinion in Immunology·T KawaiA B Cosimi
Jun 26, 1998·Transplant Immunology·G MengJ M Thomas
Mar 3, 1998·Journal of the American College of Surgeons·D W Hanto
Feb 3, 2000·Journal of the American College of Surgeons·J C McDonald
Jan 5, 2002·Veterinary Surgery : VS·Andrew E KylesRandall E Morris
May 5, 2005·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Prue HillGiuseppe Remuzzi
Sep 9, 2005·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Herman Waldmann, Geoff Hale
Sep 9, 2005·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Douglas A HaleAllan D Kirk
Sep 9, 2005·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Stuart J Knechtle
Dec 23, 2004·Transplant International : Official Journal of the European Society for Organ Transplantation·Allan D KirkDouglas A Hale
Jun 14, 2005·The Journal of Clinical Investigation·Hisashi BashudaKo Okumura
Jan 22, 2000·The Journal of Clinical Investigation·C A HuangD H Sachs
Feb 26, 2014·Transplantation Research·Peter J Friend
Nov 19, 2009·Drug Design, Development and Therapy·Phuong-Thu T PhamPhuong-Chi T Pham
Sep 21, 2004·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Sulaiman A Nanji, A M James Shapiro
Jan 9, 2010·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Diane R Mould, Bruce Green
Aug 5, 1997·Proceedings of the National Academy of Sciences of the United States of America·A D KirkS J Knechtle
Jan 22, 2003·Journal of Gastroenterology and Hepatology·Roy Calne
Aug 27, 2005·Expert Opinion on Biological Therapy·Sir Roy Y Calne
Jul 11, 2013·Current Opinion in Organ Transplantation·Tatsuo Kawai, David H Sachs
Jul 5, 2005·Expert Opinion on Investigational Drugs·D W Hunt, J G Levy
Jul 19, 2005·Microsurgery·Yavuz DemirMaria Z Siemionow
Dec 29, 2015·Current Opinion in Organ Transplantation·William H Kitchens, Andrew B Adams
Jul 10, 2007·Seminars in Nephrology·Kenneth A Newell, Christian P Larsen
Feb 15, 2005·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Jonathan P PearlAllan D Kirk
Apr 9, 2005·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Edwin H PrestonAllan D Kirk
Dec 16, 2004·Pediatric Transplantation·Nancy R Krieger, Sukru Emre
Oct 13, 2004·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Margreet JonkerRoland Foulkes
Feb 19, 2005·Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·Roy Y Calne

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.